Got Your Shots? News

MDH logo

Got Your Shots? News

View this as a webpage


Metro measles outbreak prompts accelerated vaccine recommendation

As of Aug. 27, there have been 36 confirmed cases of measles reported in Minnesota in 2024. Thirty of these cases have occurred since July and are associated with community spread. Thirty-five of 36 cases have been in unvaccinated children.

The Minnesota Department of Health (MDH) released a Health Advisory: Metro Measles Outbreak and Vaccine Recommendations urging Twin Cities health care providers that care for patients in communities with high numbers of unvaccinated and under-vaccinated children living in the metropolitan area to consider accelerating the 2-dose MMR series for children 12 months and older.

  • Administer the first dose of MMR on (or as soon as possible after) the first birthday, followed by a second dose 28 days later.
  • Administer the second MMR dose now if it has been at least 28 days since the first MMR dose and no other live virus injectable vaccines (i.e., varicella vaccine) have been administered in the past 28 days.

Families who have refused MMR vaccine in the past may be looking for more information. Use this opportunity and information for outreach: 


The Minnesota Vaccines for Children (MnVFC) program celebrates 30 years!

MDH would like to thank the over 750 health care sites in the state enrolled in the Minnesota Vaccines for Children (MnVFC) program. The Centers for Disease Control and Prevention (CDC) recently referred to the VFC program as “one of the nation’s most important contributions to health equity.”

MnVFC sites serve approximately half of the children in Minnesota by ensuring cost is not a barrier to vaccines for children who are uninsured, enrolled in a Minnesota health care program like Medical Assistance or MinnesotaCare, or children who are American Indian or Alaska Natives. Nationally, the VFC program has prevented more than 1.1 million deaths thanks to your efforts.

Help us celebrate and promote the MnVFC program by sharing our short superhero video available in multiple languages to your social media accounts.


Are Your Kids Ready? update

We recently updated the “Are Your Kids Ready? (AYKR)” resource based on feedback we received to streamline and simplify the information for parents. This resource is used to communicate the Minnesota school and child care immunization requirements to parents. As part of this update, we combined the immunization exemption form and the AYKR resource into a single two-sided document. There have not been any changes to the immunization requirements for schools and child cares. Only the formatting of the documents has changed.

If you linked to the previous version of the AYKR resources or the immunization exemption form on your webpage, please update your pages using the new the links found at Vaccines for Infants, Children, and Adolescents.

If you have questions about the updates, contact us at health.aisr@state.mn.us.

Respiratory season vaccination guidance

Now is the time to prepare and begin recommending flu, COVID-19, and RSV vaccination to all eligible people for the 2024-2025 respiratory season. CDC has published their updated recommendations and MDH respiratory season resources are being revised.

For additional information, visit:

Important notes to consider for this respiratory season

  • Respiratory Syncytial Virus (RSV)
    • RSV recommendations for older adults transitioned away from shared clinical decision-making. People 75 years of age and older and 60 through 74 years of age who are at increased risk of severe RSV disease are recommended to receive a single dose of RSV vaccine. To learn more about risk factors, visit CDC: Healthcare Providers: RSV Vaccination for Adults 60 Years of Age and Over.
    • Adults who have already received a dose of RSV vaccine do not need to receive another dose this year.
    • Recommendations for RSV during pregnancy and the use of nirsevimab for infants and young children have not changed from the 2023-2024 season. Immunization can begin according to eligibility and timing outlined in these recommendations.
  • Influenza (Flu)
    • High-dose and adjuvanted inactivated influenza vaccines are recommended as acceptable options for people 18 through 64 years of age who have had a solid organ transplant.
  • COVID-19
    • Prepare to offer the 2024-2025 COVID-19 vaccine year-round according to the Advisory Committee on Immunization Practices (ACIP) recommendations. COVID-19 has peaks in winter and at other times of the year, including the summer.  

Summer babies need RSV protection, too!

RSV is the leading cause of infant hospitalization in the U.S. There are two immunization options for protecting infants from RSV in the upcoming respiratory season: 

  • Abrysvo (Pfizer): RSV vaccine for pregnant persons.
  • Nirsevimab (Beyfortus): A monoclonal antibody immunization for infants.

The maternal vaccine can be administered to pregnant persons 32 to 36 weeks gestation between Sept. 1 and Jan. 31. The infant product can be administered between Oct. 1 and March 31. Families must choose to receive either the maternal vaccine or the infant product. 

RSV vaccone (Abrysvo) recommended during week 32-36 of pregnancy

Additional considerations:

  • Abrysvo is not recommended in subsequent pregnancies. Babies born to persons who received Abrysvo during a previous pregnancy should be immunized with nirsevimab. 
  • Clinics may need more 100mg doses of nirsevimab on hand earlier in the season.
    • All infants born this past summer or early fall (April-September) will be eligible to receive nirsevimab starting on Oct. 1.
    • Some infants/young children 8 to 19 months old entering their second RSV season are recommended to receive a second dose of nirsevimab. This includes American Indian/Alaskan native children and those at high risk for RSV complications CDC: Vaccines & Immunizations: Child Immunization Schedule Notes.
  • Nirsevimab is highly effective at protecting infants from RSV-associated hospitalization and acute respiratory episodes. For more information on RSV, visit CDC: RSV: Immunizations to Protect Infants and Respiratory Syncytial Virus (RSV) for Health Professionals.

New COVID-19 formulation

On Aug. 22, the U.S. Food and Drug Administration (FDA) took action approving and authorizing for emergency use of updated mRNA COVID-19 vaccines, FDA: FDA Approves and Authorizes Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants.

As part of FDA’s actions, the 2023–2024 Moderna and Pfizer-BioNTech COVID-19 vaccines are no longer authorized for use in the United States and should not be administered. Providers should remove all 2023-2024 COVID-19 vaccines from storage units immediately, even if they are not expired. Novavax is expected to be approved soon.

The ACIP recommends that everyone 6 months and older gets vaccinated with the updated 2024-2025 vaccine. This updated vaccine matches more closely the currently circulating strains. Most previously vaccinated people only need one dose. Visit the CDC: Interim Clinical Considerations for Use of COVID-19 Vaccines for details on children less than 5 years and immunocompromised people who may need more than one dose.


Use caution entering flu vaccine into MIIC this season

Direct Data Entry Immunization (1)

Updated 2024-2025 flu vaccines will all be trivalent and will protect against H1N1, H3N2 and B/Victoria lineage virus.

There will be no quadrivalent flu vaccines this season. Providers entering data by hand into MIIC for the 2024-2025 season should ensure they select the trivalent version of the vaccine trade name.

Download version for print

Find previous newsletters at Got Your Shots? News.